The CAPS Medical solution overcomes the challenges of delivering NTAP to internal organs, selectively destroying cancer cells without damaging surrounding healthy tissue.
19.3 Million new cancer cases worldwide annually. The company’s first area of focus Non-muscle invasive bladder cancer (NMIBC). U.S. figures: 500k sufferers; 80k new patients annually.
CAPS plans to apply its solution to additional cancer types including lung, liver, breast, gastrointestinal, and others. CAPS Medical’s solution is on track to make a profound and needed impact.